ARS Pharmaceuticals, Inc. (SPRY) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending December 2025, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is held by 4 institutional firms.

• These investors collectively held 0.1% of the company's total shares outstanding in December 2025, down from 85.8% in September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 101.93%, with a year-over-year a decrease of 97.58% in the count of filers.
• A review of institutional activity for ARS Pharmaceuticals shows 2 of 4 filers increasing their positions, while 2 reduced their stake, and 0 remained unchanged.
• Collectively, institutional investors increased their stake in ARS Pharmaceuticals to 131.19K shares as of December 2025, a change that is up by 66.22K shares quarter on quarter and down 71.19Mn shares year over year.
• SG Americas Securities, LLC's holding of 76.20K shares as of December 31, 2025 makes it the primary institutional investor in ARS Pharmaceuticals, owning 0.08% of the stock.
• Among the most significant buyers of ARS Pharmaceuticals during December 2025 were SG Americas Securities, LLC (66.10K), Versant Capital Management, Inc (1.23K).
• Leading sellers of ARS Pharmaceuticals stock in December 2025 included Permanent Capital Management, LP (1.03K), GAMMA Investing LLC (71).
• The top 4 institutional holders of ARS Pharmaceuticals for the quarter ending December 2025 included SG Americas Securities, LLC (76.20K), Permanent Capital Management, LP (52.31K), Versant Capital Management, Inc (2.57K), GAMMA Investing LLC (108).